ELUT logo

ELUT Elutia Inc

NASDAQ Capital Market · Biotechnology · Healthcare

$0.81
-0.02 (-2.41%)

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm…

Market Cap: $35.87Melutia.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
60
2 mentions
—
60d
41
5 mentions
—
90d
36
6 mentions
—
news: 6

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 0Sell 0Strong Sell 0
Avg price target$8.88+996.3%
Low $5Median $10High $10.5
Current Consensus

Revenue

$1.14M-90.10%
$1.14M$4.98M$8.82M$12.66M
Sep 2021Sep 2026

Analyst Estimates

FY2025
$-0.48
$-0.48–$-0.48
1 analysts
FY2026
$-0.66
$-0.66–$-0.66
1 analysts
FY2027
$-0.63
$-0.63–$-0.63
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
C. Randal Mills
Sector
Healthcare
Industry
Biotechnology
Employees
26
Beta
0.92
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
-6.25
elutia.com